MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines

Abstract excerpt

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the most common cause of lung cancer death. Currently, the epidermal growth factor receptor inhibitor gefitinib is used for its treatment; however, drug resistance is a major obstacle. Expression of Met has been associated with both primary and acquired resistance to gefitinib, but the mechanisms regulating its expression are not fully...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Treatments and Mutations
• Share to MicroRNA in disease regulation
• Share to RNA modifications and cancer